Gopantenic acid pills 500mg, 50pcs

Composition

1 tablet contains:

Active ingredient:

calcium hopanthenate-500 mg;

excipients:

hydroxypropylmethylcellulose (hypromellose) – 15.0 mg,

magnesium hydroxycarbonate pentahydrate (basic water magnesium carbonate) – 80.2 mg,

talc-18.6 mg;

calcium stearate-6.2 mg

Pharmacological action

Pharmacodynamics

The spectrum of action of hopantenic acid is associated with the presence of gamma-aminobutyric acid in its structure. The mechanism of action is due to the direct effect of the drug on the GABA_B-receptor-channel complex. The drug has a nootropic and anticonvulsant effect. Increases the brain’s resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, activates mental and physical performance. Improves GABA metabolism during chronic alcohol intoxication and after ethanol withdrawal. It is able to inhibit acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically elevated cystic reflex and detrusor tone.

Pharmacokinetics

Hopantenic acid is rapidly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier, and the highest concentrations are created in the liver, kidneys, stomach wall, and skin. The drug is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken is in the urine,28.5% is in the feces.

Indications

• cognitive disorders in organic brain lesions, including the consequences of neuroinfections and traumatic brain injury and neurotic disorders;
• in extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with therapy;
• as a corrector in side effects antipsychotics, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), in the complex therapy for cerebral organic insufficiency in patients with schizophrenia;
• epilepsy with slowing of mental processes in complex therapy with anticonvulsants;
• psycho-emotional overload, reduced mental and physical performance, to improve concentration and memory;
• neurogenic disorders of urination (pollakiuria, urgency imperative, imperative urinary incontinence, enuresis);
• children with developmental delay (mental, language, and motor or combinations thereof), including on the background of suffering perinatal encephalopathy in children with different forms of cerebral palsy;
• children with hyperkinetic disorder (hyperactivity disorder with attention deficit);
• children with neurotic-like States (ticks; stuttering, mostly in the form of clonic).

Use during pregnancy and lactation

It is not recommended to use the drug during pregnancy and lactation due to the lack of experience in clinical use in this category of patients.

Contraindications

• hypersensitivity;
• acute severe kidney diseases;
• pregnancy;
• breast-feeding period;
• children under 3 years of age.

With caution

In conditions of long-term treatment, simultaneous use of the drug with other nootropic and stimulating agents is not recommended.

Side effects

The adverse reactions listed below are listed according to organ and system involvement and frequency of occurrence. The frequency of occurrence is defined as follows: very common (≥ 1/10), common (≥ 1/100 and < 1/10), uncommon (≥ 1/1,000 and < 1/100), rare (≥ 1/10,000 and < 1/1,000), very rare (

Immune system disorders.

Very rare: allergic reactions (rhinitis, conjunctivitis, allergic skin reactions).

Nervous system disorders.

Very rare: hyperexcitation, headache, dizziness, noise in the head.

Mental disorders.

Very rare: lethargy, lethargy, sleep disorders, drowsiness.

In case of disorders of the immune system, the drug is canceled. In other cases, reduce the dose of the drug.

Interaction

Prolongs the action of barbiturates, enhances the effect of anticonvulsants, prevents side effects of phenobarbital, carbamazepine, neuroleptics. The effect of the drug Hopantenic acid is enhanced in combination with glycine, ethidronic acid. Potentiates the action of local anesthetics (procaine).

How to take, course of use and dosage

Inside,15-30 minutes after eating.

A single dose for adults is usually 250-1000 mg, for children-250-500 mg; a daily dose for adults-1500 mg to 3000 mg, for children – from 750 mg to 3000 mg. The course of treatment is from 1 to 4 months, in some cases-up to 6 months. After 3-6 months, it is possible to conduct a second course of treatment.

For cognitive disorders, organic brain damage, including the consequences of neuroinfections and traumatic brain injuries, and neurotic disorders: 250 mg 3-4 times a day.

For extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with the current therapy: at a dose of 500 mg to 3000 mg per day. The course of treatment is up to 4 months or more.

As a corrector for the side effect of neuroleptics, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic insufficiency in patients with schizophrenia: adults – at a dose of 500 mg to 1000 mg 3 times a day; children-at a dose of 250 mg to 500 mg 3-4 times a day. The course of treatment is 1-3 months.

For epilepsy with slowing mental processes in complex therapy with anticonvulsants: adults – at a dose of 500 mg to 1000 mg 3 times a day; children-at a dose of 250 mg to 500 mg 3-4 times a day. The course of treatment is up to 6 months.

For psychoemotional overload, reduced mental and physical performance, to improve concentration and memorization: 250 mg 3 times a day.

For neurogenic urination disorders: adults – at a dose of 500 mg to 1000 mg 2-3 times a day; children-at a dose of 250 mg to 500 mg 3 times a day (the daily dose is 25-50 mg/kg). The course of treatment is 1-3 months.

Children with various pathologies of the nervous system, depending on their age, are recommended to take the drug up to 3000 mg per day. Tactics of prescribing the drug: increasing the dose for 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until Hopantenic acid is discontinued for 7-8 days. The interval between the course of Hopantenic acid use, as for any other nootropic agent, is from 1 to 3 months.

Children with developmental delay: 500 mg 3-4 times a day. The course of treatment is 2-3 months.

Children with attention deficit hyperactivity disorder: depending on body weight, the drug is prescribed at an average therapeutic dose of 30 mg/kg per day, morning and afternoon, with titration of the dose for the first 5-7 days. The course of treatment is 3-4 months.

Children with neurosis-like conditions (tics, stuttering, mainly in tonic form): in a dose of 250 mg to 500 mg 3-6 times a day. The course of treatment is 1-4 months.

Taking into account the nootropic effect of the drug, it is preferably taken in the morning and afternoon hours (up to 17 hours).

The drug is used in children over 3 years of age. At an earlier age, it is recommended to take the drug in the form of syrup.

Overdose

Symptoms: sleep disturbances or drowsiness, noise in the head. Treatment: activated charcoal, gastric lavage, symptomatic therapy.

Description

Tablets are white or almost white in color, round, flat-cylindrical with a chamfer and a risk on one side.

Special instructions

The drug is used in children over 3 years of age.

In conditions of long-term treatment, simultaneous use of the drug with other nootropic and stimulating agents is not recommended.

Influence on the ability to drive motor vehicles and manage mechanisms

In the first days of taking the drug, care should be taken when driving vehicles and mechanisms, taking into account the possible occurrence of drowsiness.

Form of production

Tablets 250 mg and 500 mg.

10 tablets in a cell contour package made of PVC film and aluminum foil.

20 tablets each in polymer cans of the BP type made of low-density polyethylene with lids made of high-density polyethylene or in polymer bottles made of low-density polyethylene with lids made of high-density polyethylene.

Each jar or bottle,4,5,6 cell contour packages together with the instructions for use are placed in a cardboard pack.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 ° C. Keep out of reach of children.

Shelf

life is 3 years. Do not use after the expiration date indicated on the package.

Active ingredient

Hopanthenic acid

Conditions of release from pharmacies

By prescription

Dosage form

Tablets